Boston Scientific News

Fitch Ratings and Standard & Poor's currently rate the Company's corporate credit as investment grade at BBB-, with a stable outlook.

On the flip side, just 846 BSX calls changed hands during the course of the session.

This webcast is being hosted by Leerink Swann. A The replay will be archived and available at www.bostonscientific.com/investors beginning approximately one hour following the completion of the question and answer session.

Boston Scientific Corporation A posted lower net income in the fourth quarter compared with a year-earlier period.

A The Expect 19 Flex Needle is designed with a Nitinol construction for improved flexibility compared to existing EUS-Fine Needle Aspiration devices and a large diameter for expanded diagnostic capabilities.A Endoscopic ultrasound is a non-surgical, less-invasive procedure that uses high-frequency sound waves to produce detailed images of the ... (more)

Boston Scientific 's stock had its "sell" rating reiterated by Goldman Sachs in a research note issued on Friday.

Boston Scientific Corporation announces financial results for the fourth quarter and full year ended December 31, 2011, as well as sales and earnings per share guidance for the first quarter and full year 2012.

The challenges of Boston Scientific Corporation 's core segments consisting of stents and defibrillators do not show any sign of abatement.

Boston Scientific Announces CE Mark Approval and European Launch for New Infiniona 16 Percutaneous Lead for Precision Plusa Spinal Cord Stimulator System Boston Scientific Corporation announces CE Mark approval of the Infiniona 16 Percutaneous Lead for its Precision Plusa Spinal Cord Stimulator System, the first rechargeable SCS device for chronic ... (more)

In a bid to bolster its vascular business, therapeutic and diagnostic devices maker AngioDynamics has agreed to buy Massachusetts-based privately held Navilyst Medical in a cash and stock deal.

The seemingly never-ending road to recovery just got a little longer for Boston Scientific .

Citigroup Inc. : As Xstrata and Glencore discuss a merger, each side is lining up advisers, reports Reuters.

S&P 500 component Boston Scientific Corporation posted lower net income in the fourth quarter compared with a year-earlier period.

Boston Scientific Corp., the second- biggest cardiac-device maker, fell in early trading after fourth-quarter earnings plummeted 55 percent.

Boston Scientific Corp . will unveil its latest earnings on Thursday, February 2, 2012.

Edward Owens has managed Vanguard's Health Care Fund since its inception in 1984.

S&P 500 component Boston Scientific Corp. will unveil its latest earnings on Thursday, February 2, 2012.

Wall Street is expecting lower profit for Boston Scientific when the company reports its fourth quarter results on Thursday, February 2, 2012.

Chicago, IL January 26, 2012 Zacks.com announces the list of stocks featured in the Analyst Blog.

Boston Scientific welcomes new guidance from the National Institute for Health and Clinical Excellence on the use of Bronchial Thermoplasty to treat adult patients with severe asthma that is not well controlled with medications.